<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05625997</url>
  </required_header>
  <id_info>
    <org_study_id>RO-220203</org_study_id>
    <nct_id>NCT05625997</nct_id>
  </id_info>
  <brief_title>Shockwave IVL + DCB</brief_title>
  <official_title>Intravascular Lithotripsy Plus Drug-coated Balloon in Calcified Small Coronary Vessels: a Feasibility Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rede Optimus Hospitalar SA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rede Optimus Hospitalar SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug-eluting stent (DES) implantation as interventional strategy for lesions in small&#xD;
      coronary arteries is the current standard of care in many centers worldwide, but is&#xD;
      associated with increased risk of late treatment failure in small vessels, as compared with&#xD;
      larger coronary arteries. Randomized and observational studies have been shown that coronary&#xD;
      intervention with drug-coated balloons (DCB) provide a promising alternative to DES&#xD;
      implantation in small vessels, while avoiding the risk of a permanent vascular implant.&#xD;
      Furthermore, lesions in small vessels are frequently concomitant with diffuse disease and/or&#xD;
      distal location, where the presence of calcification is an additional common feature.&#xD;
      Intravascular lithotripsy (IVL) has been recently introduced as a novel adjunctive technology&#xD;
      to treat calcified lesions.&#xD;
&#xD;
      This study will explore the hypothesis that IVL has the potential to enhance the results of&#xD;
      coronary balloon dilatation of small vessels with calcified lesions, therefore increasing the&#xD;
      likelihood of optimal DBC intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2023</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Successful IVL plus DCB</measure>
    <time_frame>at 1 month follow-up</time_frame>
    <description>Successful IVL plus DCB in the absence of target lesion failure (TLF)</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Calcified Lesions in Small Coronary Vessels</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diminished blood flow in their calcified small coronary vessels&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Coronary artery disease with percutaneous intervention clinically indicated to treat&#xD;
             one or more lesions fulfilling all criteria below:&#xD;
&#xD;
               -  De novo lesion with diameter stenosis &gt; 50% (visual analysis)&#xD;
&#xD;
               -  Coronary vessel diameter &lt; 3.0 mm (visual analysis)&#xD;
&#xD;
               -  Severe calcification at the target segment, defined as fluoroscopic radiopacities&#xD;
                  noted without cardiac motion prior to contrast injection involving both sides of&#xD;
                  the arterial wall in at least 1 location OR Intravascular Ultrasound/Optical&#xD;
                  Coherence Tomography (IVUS/OCT) demonstrated calcium angle of ≥270° on at least 1&#xD;
                  cross section.&#xD;
&#xD;
          3. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous coronary intervention at or &lt; 10 mm distant from target segment at any time.&#xD;
&#xD;
          2. Lesion length ≥ 40 mm.&#xD;
&#xD;
          3. Planned atherectomy or cutting/scoring balloon use.&#xD;
&#xD;
          4. Bifurcation lesion.&#xD;
&#xD;
          5. Thrombus containing lesion.&#xD;
&#xD;
          6. Life expectancy &lt; 12 months due to other co-morbid condition(s) that could limit&#xD;
             patient's ability to participate in clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio Ribichini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita di Verona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro Lemos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Israelita Albert Einstein, São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annelena Held-Wehmöller, PhD</last_name>
    <phone>+4915785128140</phone>
    <email>info@fcre.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Pedro Lemos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Flavio Ribichini, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 15, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>November 15, 2022</last_update_submitted>
  <last_update_submitted_qc>November 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

